Combined with literature reports implicating KMT2C in chemotherapy response in hemopoeitic malignancies [77] and solid tumors [20], our findings uncover a broader role for KMT2C in modulating therapeutic response in neoplasia. This evidence concerns the gene KMT2C and neoplasm.